Golbi Tablet for Cholelithiasis
I cannot recommend Golbi tablet for cholelithiasis because the FDA drug label evidence 1 indicates Golbi is a topical healing balm applied to skin, not an oral medication for gallstones.
Critical Clarification
The provided "Golbi" drug label describes a topical product with directions stating "Apply to affected area not more than 3 to 4 times daily" 1. This is clearly not ursodeoxycholic acid (UDCA) for gallstone dissolution. There appears to be a mismatch between the question and the drug label provided.
If You Mean Ursodeoxycholic Acid (UDCA) for Gallstones
Assuming you're asking about UDCA therapy for cholesterol gallstones, here is the evidence-based approach:
Patient Selection is Critical
UDCA should only be used in highly selected patients with cholesterol gallstones who are not surgical candidates 2. The American College of Physicians guidelines emphasize that suitable candidates account for only 20% of cholecystectomy patients 2.
Strict Inclusion Criteria
UDCA works ONLY when:
- Stone composition: Radiolucent (cholesterol-rich, non-calcified) stones 3, 4
- Stone size: Less than 10-15 mm diameter (ideally <6 mm) 3, 5, 4
- Stone number: Single or few stones (≤3) 3
- Gallbladder function: Patent cystic duct with functioning gallbladder confirmed by oral cholecystography 3
- Stone characteristics: Floating stones have 83.3% efficacy 5
Dosing Regimen
The optimal dose is 8-10 mg/kg/day given as a single bedtime dose 6, 7, 4:
- Bedtime administration reduces the minimum effective dose compared to mealtime dosing 6
- In one study, 7 mg/kg/day at bedtime achieved cholesterol saturation index of 0.73 versus 0.81 with 10 mg/kg/day at mealtime 6
- Typical adult dose: 600 mg/day 5
- Doses ≤600 mg/day show better compliance and outcomes 8
Duration and Monitoring
- Treatment duration: 6 months to 2 years 2, 7
- Response timeline: Partial dissolution may occur within 6 months; complete dissolution requires continued therapy 4
- Success rates: 40-55% overall; up to 80% in carefully selected patients with optimal stone characteristics 4
- Symptom relief: Most biliary symptoms disappear within 3 months 7
Critical Limitations and Pitfalls
Major drawbacks that must be discussed with patients:
- Recurrence is the rule: Approximately 50% of patients experience gallstone recurrence after successful dissolution 3
- Does NOT prevent gallbladder cancer 2
- Does NOT prevent future gallstone formation 2
- Limited efficacy: Large stones (>15 mm) and calcified stones unlikely to respond 4
- Long treatment duration: Daily therapy for up to 2 years 2
Safety Profile
UDCA is remarkably well tolerated 7, 4:
- Diarrhea occurs in only a very small proportion of patients 4
- No adverse effects on liver function tests 7
- No increase in biliary lithocholic acid concentration 7
Clinical Context and Recommendation
Laparoscopic cholecystectomy remains the treatment of choice for symptomatic cholelithiasis 3. UDCA is indicated only for:
- Patients unfit for surgery 3
- Patients who refuse surgery 3
- Highly selected patients meeting all inclusion criteria above
The American College of Physicians guidelines emphasize that surgical cholecystectomy prevents future pain, complications, gallstone recurrence, and gallbladder cancer—outcomes that UDCA cannot achieve 2. Recent evidence from 2023 confirms clinical equipoise exists, with 95% of surveyed clinicians stating they would need RCT evidence before routinely using UDCA 9.
For the specific "Golbi tablet" mentioned in your question, please verify the actual product name and formulation, as the provided drug label does not match an oral gallstone dissolution therapy.